Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-α agonist treatment

Melanie G. Cree, Bradley R. Newcomer, Laura K. Read, Melinda Sheffield-Moore, Douglas Paddon-Jones, David Chinkes, Asle Aarsland, Robert R. Wolfe

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Increases in plasma lipids, tissue triglycerides and decreases in mitochondrial function have been linked to insulin resistance and aging. In animals, peroxisome proliferator-activated receptor-α (PPAR-α) agonists decrease plasma lipids, intramyocellular fat (IMCL) and liver fat (LFAT) and improve mitochondrial β-oxidative function and insulin sensitivity, but the effects in elderly were not known. Insulin sensitivity was assessed with a 2-h oral glucose tolerance test, magnetic resonance spectroscopy was used to asses IMCL, LFAT and plasma lipids were measured before and after 6, 11 and 61 days of PPAR-α agonist (fenofibrate) administration in 19 elderly (age 70 ± 1 years) volunteers. Volunteers were stratified into healthy (N = 7) and insulin resistant (N = 12) groups. The baseline insulin sensitivity index (8.1 ± 1.2 vs. 3.8 ± 0.5, healthy vs. insulin resistant; P < 0.001) was significantly higher in the healthy group. Fenofibrate treatment induced significant reductions in plasma triglycerides (P < 0.001) and total cholesterol (P < 0.001) in both groups. Nonetheless, neither fasted free fatty acids, glucose, insulin, nor insulin sensitivity improved in either group (day 1 vs. day 61, 8.1 ± 1.2 vs. 8.1 ± 0.9, healthy; and 3.8 ± 0.5 vs. 4.2 ± 0.05, insulin resistant). Furthermore, there was no change in IMCL or LFAT. These results indicate that whereas fenofibrate significantly lowers plasma lipids it neither affects insulin sensitivity nor intracellular lipids in elderly.

Original languageEnglish
Pages (from-to)558-565
Number of pages8
JournalMechanisms of Ageing and Development
Volume128
Issue number10
DOIs
StatePublished - Oct 2007

Fingerprint

Peroxisome Proliferator-Activated Receptors
Insulin Resistance
Triglycerides
Fats
Insulin
Tissue
Fenofibrate
Lipids
Plasmas
Volunteers
Liver
Therapeutics
Equidae
Glucose Tolerance Test
Nonesterified Fatty Acids
Magnetic resonance spectroscopy
Magnetic Resonance Spectroscopy
Glucose
Cholesterol
Animals

Keywords

  • Aging
  • Insulin resistance
  • Intramuscular triglyceride
  • Liver fat
  • Plasma lipids

ASJC Scopus subject areas

  • Aging
  • Biochemistry
  • Developmental Biology
  • Developmental Neuroscience

Cite this

Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-α agonist treatment. / Cree, Melanie G.; Newcomer, Bradley R.; Read, Laura K.; Sheffield-Moore, Melinda; Paddon-Jones, Douglas; Chinkes, David; Aarsland, Asle; Wolfe, Robert R.

In: Mechanisms of Ageing and Development, Vol. 128, No. 10, 10.2007, p. 558-565.

Research output: Contribution to journalArticle

Cree, Melanie G. ; Newcomer, Bradley R. ; Read, Laura K. ; Sheffield-Moore, Melinda ; Paddon-Jones, Douglas ; Chinkes, David ; Aarsland, Asle ; Wolfe, Robert R. / Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-α agonist treatment. In: Mechanisms of Ageing and Development. 2007 ; Vol. 128, No. 10. pp. 558-565.
@article{4b5a6112fb9d4d899d68493cf6a6dfb4,
title = "Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-α agonist treatment",
abstract = "Increases in plasma lipids, tissue triglycerides and decreases in mitochondrial function have been linked to insulin resistance and aging. In animals, peroxisome proliferator-activated receptor-α (PPAR-α) agonists decrease plasma lipids, intramyocellular fat (IMCL) and liver fat (LFAT) and improve mitochondrial β-oxidative function and insulin sensitivity, but the effects in elderly were not known. Insulin sensitivity was assessed with a 2-h oral glucose tolerance test, magnetic resonance spectroscopy was used to asses IMCL, LFAT and plasma lipids were measured before and after 6, 11 and 61 days of PPAR-α agonist (fenofibrate) administration in 19 elderly (age 70 ± 1 years) volunteers. Volunteers were stratified into healthy (N = 7) and insulin resistant (N = 12) groups. The baseline insulin sensitivity index (8.1 ± 1.2 vs. 3.8 ± 0.5, healthy vs. insulin resistant; P < 0.001) was significantly higher in the healthy group. Fenofibrate treatment induced significant reductions in plasma triglycerides (P < 0.001) and total cholesterol (P < 0.001) in both groups. Nonetheless, neither fasted free fatty acids, glucose, insulin, nor insulin sensitivity improved in either group (day 1 vs. day 61, 8.1 ± 1.2 vs. 8.1 ± 0.9, healthy; and 3.8 ± 0.5 vs. 4.2 ± 0.05, insulin resistant). Furthermore, there was no change in IMCL or LFAT. These results indicate that whereas fenofibrate significantly lowers plasma lipids it neither affects insulin sensitivity nor intracellular lipids in elderly.",
keywords = "Aging, Insulin resistance, Intramuscular triglyceride, Liver fat, Plasma lipids",
author = "Cree, {Melanie G.} and Newcomer, {Bradley R.} and Read, {Laura K.} and Melinda Sheffield-Moore and Douglas Paddon-Jones and David Chinkes and Asle Aarsland and Wolfe, {Robert R.}",
year = "2007",
month = "10",
doi = "10.1016/j.mad.2007.08.001",
language = "English",
volume = "128",
pages = "558--565",
journal = "Mechanisms of Ageing and Development",
issn = "0047-6374",
publisher = "Elsevier Ireland Ltd",
number = "10",

}

TY - JOUR

T1 - Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-α agonist treatment

AU - Cree, Melanie G.

AU - Newcomer, Bradley R.

AU - Read, Laura K.

AU - Sheffield-Moore, Melinda

AU - Paddon-Jones, Douglas

AU - Chinkes, David

AU - Aarsland, Asle

AU - Wolfe, Robert R.

PY - 2007/10

Y1 - 2007/10

N2 - Increases in plasma lipids, tissue triglycerides and decreases in mitochondrial function have been linked to insulin resistance and aging. In animals, peroxisome proliferator-activated receptor-α (PPAR-α) agonists decrease plasma lipids, intramyocellular fat (IMCL) and liver fat (LFAT) and improve mitochondrial β-oxidative function and insulin sensitivity, but the effects in elderly were not known. Insulin sensitivity was assessed with a 2-h oral glucose tolerance test, magnetic resonance spectroscopy was used to asses IMCL, LFAT and plasma lipids were measured before and after 6, 11 and 61 days of PPAR-α agonist (fenofibrate) administration in 19 elderly (age 70 ± 1 years) volunteers. Volunteers were stratified into healthy (N = 7) and insulin resistant (N = 12) groups. The baseline insulin sensitivity index (8.1 ± 1.2 vs. 3.8 ± 0.5, healthy vs. insulin resistant; P < 0.001) was significantly higher in the healthy group. Fenofibrate treatment induced significant reductions in plasma triglycerides (P < 0.001) and total cholesterol (P < 0.001) in both groups. Nonetheless, neither fasted free fatty acids, glucose, insulin, nor insulin sensitivity improved in either group (day 1 vs. day 61, 8.1 ± 1.2 vs. 8.1 ± 0.9, healthy; and 3.8 ± 0.5 vs. 4.2 ± 0.05, insulin resistant). Furthermore, there was no change in IMCL or LFAT. These results indicate that whereas fenofibrate significantly lowers plasma lipids it neither affects insulin sensitivity nor intracellular lipids in elderly.

AB - Increases in plasma lipids, tissue triglycerides and decreases in mitochondrial function have been linked to insulin resistance and aging. In animals, peroxisome proliferator-activated receptor-α (PPAR-α) agonists decrease plasma lipids, intramyocellular fat (IMCL) and liver fat (LFAT) and improve mitochondrial β-oxidative function and insulin sensitivity, but the effects in elderly were not known. Insulin sensitivity was assessed with a 2-h oral glucose tolerance test, magnetic resonance spectroscopy was used to asses IMCL, LFAT and plasma lipids were measured before and after 6, 11 and 61 days of PPAR-α agonist (fenofibrate) administration in 19 elderly (age 70 ± 1 years) volunteers. Volunteers were stratified into healthy (N = 7) and insulin resistant (N = 12) groups. The baseline insulin sensitivity index (8.1 ± 1.2 vs. 3.8 ± 0.5, healthy vs. insulin resistant; P < 0.001) was significantly higher in the healthy group. Fenofibrate treatment induced significant reductions in plasma triglycerides (P < 0.001) and total cholesterol (P < 0.001) in both groups. Nonetheless, neither fasted free fatty acids, glucose, insulin, nor insulin sensitivity improved in either group (day 1 vs. day 61, 8.1 ± 1.2 vs. 8.1 ± 0.9, healthy; and 3.8 ± 0.5 vs. 4.2 ± 0.05, insulin resistant). Furthermore, there was no change in IMCL or LFAT. These results indicate that whereas fenofibrate significantly lowers plasma lipids it neither affects insulin sensitivity nor intracellular lipids in elderly.

KW - Aging

KW - Insulin resistance

KW - Intramuscular triglyceride

KW - Liver fat

KW - Plasma lipids

UR - http://www.scopus.com/inward/record.url?scp=34848827880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848827880&partnerID=8YFLogxK

U2 - 10.1016/j.mad.2007.08.001

DO - 10.1016/j.mad.2007.08.001

M3 - Article

C2 - 17904198

AN - SCOPUS:34848827880

VL - 128

SP - 558

EP - 565

JO - Mechanisms of Ageing and Development

JF - Mechanisms of Ageing and Development

SN - 0047-6374

IS - 10

ER -